Clinical and Translational Science Award

Clinical and Translational Science Award
Name	Clinical and Translational Science Award
Established	2006
Presenter	National Institutes of Health National Center for Advancing Translational Sciences
Country	United States

Clinical and Translational Science Award The Clinical and Translational Science Award is a federal program created to accelerate translational research and foster collaborative networks among academic medical centers, industry partners, and public health agencies, with an emphasis on supporting clinical trials and workforce development. The initiative connects large research universities, medical schools, and clinical centers such as Harvard University, Johns Hopkins University, Stanford University, University of California, San Francisco, and University of Pennsylvania with federal entities like National Institutes of Health, Centers for Disease Control and Prevention, and private partners including Pfizer, Johnson & Johnson, and Genentech to translate basic science discoveries into patient-centered interventions.

History

The program was launched in 2006 under the auspices of National Institutes of Health and later administered by National Center for Advancing Translational Sciences, following precedent from initiatives at institutions such as University of Michigan, Yale University, Duke University, University of Washington, and Vanderbilt University. Early pilots involved collaborations with centers like Massachusetts General Hospital, Mayo Clinic, Cleveland Clinic, University of Chicago, and Columbia University, building on earlier translational efforts associated with Howard Hughes Medical Institute, Wellcome Trust, Medical Research Council (United Kingdom), and programs influenced by policy discussions in United States Congress and recommendations from Institute of Medicine reports. Subsequent rounds expanded the network to include partners such as Northwestern University, Emory University, University of Pittsburgh, Brown University, and New York University, reflecting shifts in federal priorities after reviews by panels including members from American Association for the Advancement of Science and Association of American Medical Colleges.

Program Structure and Governance

Governance involves oversight by National Center for Advancing Translational Sciences leadership and advisory committees comprising representatives from institutions like Yale University, Harvard University, Stanford University, Duke University, and Johns Hopkins University, with stakeholder input from organizations such as Patient-Centered Outcomes Research Institute, American Medical Association, American Association of Retired Persons, and Bill & Melinda Gates Foundation. Awardees are typically consortia linking universities, medical centers, community hospitals, and industry partners including Bristol-Myers Squibb, AstraZeneca, and Novartis, coordinated via program hubs at sites like University of California, Los Angeles, University of North Carolina at Chapel Hill, University of Wisconsin–Madison, University of Texas Southwestern Medical Center, and Oregon Health & Science University. Governance structures incorporate institutional review boards from entities such as Food and Drug Administration, data safety monitoring boards with members from Centers for Medicare & Medicaid Services, and collaborations with networks like ClinicalTrials.gov and ResearchMatch.

Funding and Eligibility

Funding is awarded through competitive grants from National Institutes of Health with significant investment by National Center for Advancing Translational Sciences, and has involved partnerships with philanthropic organizations such as Rockefeller Foundation, Robert Wood Johnson Foundation, and corporate funders including GlaxoSmithKline. Eligible applicants include academic health centers, medical schools, and research hospitals such as University of Florida, University of Colorado, Rutgers University, Penn State University, and University of Illinois Chicago, often requiring multidisciplinary teams encompassing departments from institutions like Harvard Medical School, Perelman School of Medicine at the University of Pennsylvania, Columbia University Vagelos College of Physicians and Surgeons, and Icahn School of Medicine at Mount Sinai. Awards have varied by cycle with budget lines reflecting priorities articulated by leaders at National Institutes of Health and oversight from advisory boards including members from National Science Foundation and Office of the Surgeon General.

Research and Training Activities

Activities span clinical trial support, biomarker validation, implementation science, community engagement, and workforce training with programs hosted at centers like University of California, San Diego, University of Minnesota, University of Iowa, University of Kansas Medical Center, and University of Arizona. Training pipelines connect graduate programs at Massachusetts Institute of Technology, California Institute of Technology, Johns Hopkins Bloomberg School of Public Health, and Imperial College London with clinical mentors from Mayo Clinic, Cleveland Clinic, Mount Sinai Health System, and Brigham and Women's Hospital, offering curricula in translational methods, regulatory science, and biostatistics via collaborations with Society for Clinical Trials and American Statistical Association. Research projects have included partnerships with disease-focused organizations such as American Cancer Society, Alzheimer's Association, American Heart Association, and Juvenile Diabetes Research Foundation to advance interventions in oncology, neurology, cardiology, and endocrinology.

Impact and Outcomes

The award network has supported multicenter trials and metrics of translational progress at institutions like Vanderbilt University Medical Center, University of Pennsylvania Health System, Mount Sinai, University of Colorado Anschutz Medical Campus, and University of Rochester, contributing to regulatory submissions to Food and Drug Administration, guideline updates by National Comprehensive Cancer Network, and public health responses coordinated with Centers for Disease Control and Prevention and World Health Organization. Outcomes include development of validated biomarkers implemented in clinical practice at sites such as Dana-Farber Cancer Institute, accelerated investigator training pipelines feeding academic appointments at Stanford University School of Medicine, and commercialization partnerships engaging Biogen, Amgen, Regeneron, and venture investors from Sequoia Capital and Third Rock Ventures.

Criticism and Challenges

Critiques have come from stakeholders including faculty at University of California, Berkeley, policy analysts at Brookings Institution, and commentators in outlets like The New York Times, citing concerns about sustainability, equity of resource distribution among centers like Rural Health Clinics versus major hubs such as Massachusetts General Hospital, and potential conflicts with industry partners like AbbVie and Sanofi. Operational challenges noted by administrators at University of Michigan, Duke University School of Medicine, and University of Pittsburgh Medical Center include data sharing barriers with repositories like dbGaP, regulatory complexity involving Food and Drug Administration and Office for Human Research Protections, and variability in community engagement outcomes in collaborations with organizations like National Association of Community Health Centers.

Category:Medical research in the United States